Anidulafungin in the treatment of invasive fungal infections
Therapeutics and Clinical Risk Management, 2008 Kathryn Sabol, Tawanda GumboUniversity of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: More antifungal agents have reached clinical use in the past two decades than at any other time.
Kathryn Sabol, Tawanda Gumbo
doaj
Fungal infections of the central nervous system: A review of fungal pathogens and treatment [PDF]
, 2007 Multiple factors influence the outcome of fungal infection of the central nervous system (CNS). The host and the pathogen in concert with drug delivery across the blood-brain barrier and drug activity are key factors in outcome.
Dancer, C., Redmond, A., Woods, M. L.
core +1 more source
Clinical Outcomes of Intra‐Abdominal Candidiasis by Initial Antifungal Therapy
Mycoses, Volume 69, Issue 3, March 2026.ABSTRACT Background Intra‐abdominal candidiasis (IAC) is a severe and heterogeneous infection associated with significant morbidity and mortality. Objectives To evaluate outcomes of IAC according to initial antifungal therapy and to identify predictors of persistent infection and 30‐day mortality.
M. Albanell‐Fernández +6 more
wiley +1 more source
Recent Insights into the Paradoxical Effect of Echinocandins
Journal of Fungi, 2017 Echinocandin antifungals represent one of the most important drug classes for the treatment of invasive fungal infections. The mode of action of the echinocandins relies on inhibition of the β-1,3-glucan synthase, an enzyme essentially required for the ...
Johannes Wagener, Veronika Loiko
doaj +1 more source
Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. [PDF]
, 2009 Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with 1.3 x 10(7) to 1.5 x 10(7) CFU of C. krusei.
Chen, Enuo +4 more
core
Candida auris, what do paediatricians need to know? [PDF]
, 2018 AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core +1 more source
Rapid automated antifungal susceptibility testing system for yeasts based on growth characteristics
Frontiers in Cellular and Infection Microbiology, 2023 Fungal pathogens are a major threat to public health, as they are becoming increasingly common and resistant to treatment, with only four classes of antifungal medicines currently available and few candidates in the clinical development pipeline.
Jinhan Yu +17 more
doaj +1 more source
Identification of Aspergillus cryptic species in hospital environment [PDF]
, 2015 Selected hospital wards, housing patients at higher risk to develop invasive fungal infections, were screened in order to understand the epidemiology and distribution of Aspergillus, especially regarding the presence of cryptic species.Aspergillus ...
Brandão, João +7 more
core +1 more source
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
International Journal of Infectious Diseases, 2019 Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that ...
D.V. Pérez Civantos +5 more
doaj +1 more source
Journal of Fungi, 2020 Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth +9 more
doaj +1 more source